The IPO Buzz: Biotechs Turn Up the Heat in August

Biotechs are heating up the IPO Calendar as August gets under way. Four big biotech IPOs are set to price this week – along with a smaller biotech deal. Altogether, these five deals aim to raise $972 million. The August heat wave is no surprise. U.S. biotech and pharmaceutical sector IPOs produced a weighted average return of 55 percent through late July, Bloomberg reported.

This week’s deals are coming hot on the heels of Aprimed (APMD) – closing today (Monday, Aug. 3, 2025) at $25.00 – up 56.25 percent today from its IPO price at $16.00 last Thursday, July 30th, and Scribe Therapeutics (SCTX) – closing today at $20.84 – up  38.93 percent from its IPO price of $15.00 the previous week – on Thursday, July 23rd.

 Veradermics (MANE) set the trend for the year with its moonshot – closing on Feb. 4, 2026, at $37.75 – more than double its $17.00 IPO price on its first day of trading. Fast forward to today – Monday, Aug. 3: Veradermics’ stock closed at $101.89 – nearly six times its IPO price.

Two more standouts: Parabilis Medicines (PBLS) closed today at $33.96 – up $13.96 from its IPO price of $20.00 on June 9, 2026. Hemab Therapeutics (COAG) closed today at $45.00  – more than double its $18.00 price on April 30, 2026.

One IPO – Attovia – Pricing Tuesday Night, Aug. 4, 2026, to trade Wednesday, Aug. 5:

Let’s take a look at this week’s line-up. All are NASDAQ listings.

Attovia Therapeutics (ATTO Proposed), a Phase 1 biotech developing drugs to treat chronic pruritis (itching), atopic dermatitis and IBD, is offering 12.5 million shares at a price range of $15.00 to $17.00 to rais $200 million – if priced at its $16.00 mid-point.

Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets and LifeSci Capital are the joint book-runners.

Attovia, based in San Carlos, California, plans to start Phase 1 clinical trials next year for its three drug candidates, the prospectus said. Alamar Biosciences (ALMR), which went public in mid-April, is one of Attovia’s founding shareholders. Goldman Sachs Alternatives is a principal shareholder.

Financial Snapshot: Net loss of $64.13 million on collaboration revenue of $1.35 million for the 12 months that ended on March 31,2026

Two IPOs Pricing Wednesday night, Aug. 5, 2026, to trade Thursday, Aug. 6:

Braveheart Bio (BRVE Proposed), a Phase 3 biotech developing a pill to treat hypertrophic cardiomyopathy (HCM), is offering 18.75 million shares at a price range of $15.00 to $17.00 to raise $300 million – if priced at its $16.00 mid-point.

Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are the joint book-runners.

Fidelity has indicated an interest in buying up to $75  million of stock in Braveheart Bio’s IPO, the prospectus said

Braveheart Bio’s leading drug candidate is a pill called BHB-1893, which is being evaluated to treat hypertrophic cardiomyopathy (HCM), a genetic disease that causes the heart to beat with excessive force. HCM increases the risk of heart failure and sudden cardiac death.

Braveheart Bio plans global Phase 3 trials of BHB-1893: LIONHEART-HCM, its global Phase 3 trial in oHCM, in the second half of 2026, and NOBLEHEART-HCM, its global Phase 3 trial in nHCM in the first half of 2027.

Principal shareholders include Andreessen Horowitz. Forbion and OrbiMed, the prospectus said.

Financial Snapshot: Net loss of $80.23 million on no revenue for the 12 months that ended on March 31, 2026

Vogenx (VOGX Proposed), a Phase 2 clinical biotech developing a drug to treat post-bariatric hypoglycemia, is offering 6.25 million shares at a price range of $11.00 to $13.00 to raise $75.0 million, if priced at the $12.00 mid-point of its range.

Jones is the sole book-runner.

Vogenx is evaluating its lead product candidate, mizagliflozin, a pill, in a Phase 2B study to treat post-bariatric hypoglycemia. The condition affects some people who have undergone bariatric surgery to help them lose weight. Vogenx has licensed mizagliflozin from Kissei Pharmaceutical on a worldwide basis, excluding Japan, Korea and Taiwan.

Vogenx, based in Raleigh, N.C., is also planning a Phase 2 proof-of-concept clinical trial of mizaglifozin in patients diagnosed with gastroparesis.

Financial Snapshot: Net loss of $1.56 million on no revenue for the 12 months that ended on March 31, 2026

2 IPOs Pricing Thursday night, Aug. 6, to trade Friday, Aug. 7:

BlossomHill  Therapeutics (BLSM Proposed), a Phase 2 cancer biotech, is offering 7.81 million shares at a price range of $15.00 to $17.00 to raise $125.0 million, if priced at the $16.00 mid-point of its range.

J.P. Morgan and Leerink Partners are leading the joint book-running team, which includes Guggenheim Securities, LifeSci Capital and H.C. Wainwright.

The San Diego-based biotech’s initial focus is on a certain type of non-small cell lung cancer.

BlossomHill’s leading drug candidate, BH-30643, is in SOLARA, its global Phase 1/2 trial for EGFR-mutant non-small cell lung cancer (NSCLC). The company noted that there is a fragmentation of care in EGFR-mutant NSCLC because no drug is effective across all EGFR mutations. (Note: EGFR stands for epidermal growth factor receptor.)

“We plan to seek an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026 to discuss recommended dosing for Phase 2 and a potential accelerated pathway for approval for certain patients,” BlossomHill said in the prospectus.

Principal stockholders include OrbiMed, with a 9.8 percent pre-IPO stake, and Janus Henderson, with a 5.3 percent pre-IPO stake, the prospectus said.

Financial Snapshot:  Net loss of $71.09 million on no revenue for the 12 months that ended on March 31, 2026

Latigo  Biotherapeutics (LTGO Proposed), a California biotech focused on non-opioid pain relief treatments, is offering 16 million shares at a price range of $16.00 to  $18.00 to raise $272 million, if priced at the $17.00 mid-point of its range.

Goldman Sachs, Jefferies, Leerink Partners and Guggenheim Securities are the joint book-runners.

LTG-001, Latigo’s lead candidate, is an oral Na_v1.8 Inhibitor for moderate to severe acute pain, including post-operative pain. LTG-001 is being developed as a pill and as an IV therapy.

Latigo Biotherapeutics, based in Thousand Oaks, California, is also developing LTG-321, a drug candidate to treat chronic musculoskeletal pain, starting with osteoarthritis (OA) of the knee.

Westlake BioPartners, Foresite Capital and 5 AM Ventures are also principal shareholders, along with Blue Owl Capital, according to the prospectus.

Financial Snapshot: Net loss of $111.2 million on no product revenue for the 12 months that ended on March 31, 2026

Source: https://www.iposcoop.com/the-ipo-buzz-biotechs-turn-up-the-heat-in-august/